Sun Xiaodong, Zhuang Bo, Zhang Mengmeng, Jiang Heliu, Jin Yiguang
Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China.
Institute of Pharmacy, Pharmaceutical College of Henan University, Jin Ming Avenue, Kaifeng 475004, China.
ACS Biomater Sci Eng. 2019 Feb 11;5(2):724-739. doi: 10.1021/acsbiomaterials.8b01111. Epub 2019 Jan 15.
Traditional chemotherapy of cancers may lead to serious adverse reactions due to little drug distribution in tumors. Here, a combination of photothermal therapy (PTT) and photodynamic therapy (PDT) was used for local treatment of orthotopic melanoma and breast cancer via intratumoral (i.t.) injection of photothermal agent-loaded photodynamic nanocarriers. A hydrophobic derivative of indocyanine green, DCC, was synthesized and entrapped into a pH-sensitive photosensitizer-core copolymer, PDCZP, to form DCC@PDCZP. The nanocarriers showed remarkable fluorescence, high singlet oxygen quantum yields, and a strong photothermal effect. Flow cytometry suggested that the nanocarriers were efficiently internalized by cancer cells. Near infrared thermal imaging and fluorescence self-imaging showed that the i.t. injected DCC@PDCZP mainly remained in the tumors, but the intravenous (i.v.) nanocarriers were distributed a little. One i.t. injection of DCC@PDCZP was enough to ablate the orthotopic B16-F10 and 4T1 mouse tumors under 830 and 660 nm irradiation at 4 h postinjection. More importantly, no local recurrences were found, though swabs were formed at 9 days post-treatment. The major anticancer mechanisms included improvement of cancer cell necrosis due to hyperthermia, inhibition of neovascularization, and enhancement of cell apoptosis. The i.t. injection of PTT/PDT nanoformulations is thus a promising local treatment of superficial tumors.
由于肿瘤内药物分布较少,传统的癌症化疗可能会导致严重的不良反应。在此,通过瘤内(i.t.)注射负载光热剂的光动力纳米载体,将光热疗法(PTT)和光动力疗法(PDT)联合用于原位黑色素瘤和乳腺癌的局部治疗。合成了吲哚菁绿的疏水衍生物DCC,并将其包裹在pH敏感的光敏剂-核共聚物PDCZP中,形成DCC@PDCZP。该纳米载体表现出显著的荧光、高单线态氧量子产率和强烈的光热效应。流式细胞术表明癌细胞能有效内化纳米载体。近红外热成像和荧光自成像显示,瘤内注射的DCC@PDCZP主要保留在肿瘤中,而静脉注射(i.v.)的纳米载体分布较少。在注射后4小时,一次瘤内注射DCC@PDCZP足以在830和660 nm照射下消融原位B16-F10和4T1小鼠肿瘤。更重要的是,尽管在治疗后9天形成了拭子,但未发现局部复发。主要的抗癌机制包括因热疗导致癌细胞坏死增加、抑制新血管形成和增强细胞凋亡。因此,瘤内注射PTT/PDT纳米制剂是一种有前景的浅表肿瘤局部治疗方法。